BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)’s Fodosine™ has been granted by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) an orphan drug status for the treatment of cutaneous T-cell lymphoma (CTCL).
BioCryst’s leading oncology candidate, Fodosine™ is currently under investigative clinical trials for the treatment of T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma (CTCL), B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukaemia (CLL).
Fodosine™ is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP).
The drug is currently being developed and commercialized by Mundipharma International Holdings (in a strategic collaboration with BioCryst) in markets across Europe, Asia, Australia and certain neighboring countries for oncology use.
Source: BioCryst Pharmaceuticals, Inc.
.jpg)
Comment Preview